Silo Pharma files provisional patent for CNS-homing peptides to treat Alzheimer's

Silo Pharma, Inc.

Filed provisional patent for CNS-homing peptides targeting Alzheimer's disease and dementia.
Peptides designed to reduce toxicity and improve therapeutic payload delivery to affected cells.
CEO Eric Weisblum cited unmet need for effective Alzheimer's treatments and targeted delivery approach.
Silo Pharma continues preclinical studies of novel therapeutics including psychedelic research.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.